Last reviewed · How we verify
Prospective Experimental of Tripterygium Glycoside in the Treatment of Crohn's Disease for Induction Remission
The purpose of this study is to assess the effect and safety of Tripterygium Glycosides in the treatment of Crohn's disease for induction remission and compare the therapeutic effect with patients who received mesalazine.
Details
| Lead sponsor | Zhu Weiming |
|---|---|
| Phase | Phase 2/Phase 3 |
| Status | UNKNOWN |
| Enrolment | 40 |
| Start date | 2014-01 |
| Completion | 2016-07 |
Conditions
- Inflammatory Bowel Diseases
- Crohn's Disease
- Gastrointestinal Diseases
- Digestive System Diseases
- Intestinal Diseases
Interventions
- Mesalazine, Tripterygium glycosides
Primary outcomes
- Therapeutic effect measured by Crohn's Disease Activity Index (CDAI) — 12 weeks
Countries
China